We have located links that may give you full text access.
eHealth to improve psychological functioning and self-management of people with chronic kidney disease: a randomized controlled trial.
Psychosomatic Medicine 2023 January 24
OBJECTIVE: Psychological distress is common among patients with chronic kidney disease (CKD), and can interfere with disease self-management. We assessed the effectiveness of the personalized E-GOAL eHealth care pathway with screening and cognitive-behavioral therapy including self-management support, aimed to treat psychological distress and facilitate self-management among people with CKD not on dialysis (N = 121).
METHODS: Primary outcome of the open two-arm parallel randomized controlled trial in 4 Dutch hospitals was psychological distress at post-test directly after the intervention and at 3-month follow-up. Secondary outcomes were physical and mental health-related quality of life (HRQoL), self-efficacy, chronic disease self-management, and personalized outcomes, i.e., perceived progress compared to the previous time point on functioning (e.g., mood or social functioning) and self-management (e.g., dietary or medication adherence) outcomes that were prioritized by each individual.
RESULTS: Linear mixed-effects analyses showed no significant time-by-group interaction effects for psychological distress, HRQoL, self-efficacy, and chronic condition self-management, whereas ANCOVAs showed significantly more perceived progress in the intervention group at post-test on personally prioritized areas of functioning, b = 0.46, 95%CI[0.07, 0.85], and self-management, b = 0.55, 95%CI[0.16, 0.95], with Cohen's ds of 0.46 and 0.54 (medium effects), respectively. Effects on personalized outcomes were maintained at follow-up.
CONCLUSIONS: Compared to regular care only, the eHealth intervention did not reduce psychological distress, whereas personalized outcomes did improve significantly post-intervention. Future studies could consider personalized outcomes that reflect individually relevant areas and treatment goals, matching person-tailored treatments.Trial Registration: Registered at the Netherlands Trial Register with study number NTR7555 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR7555).
METHODS: Primary outcome of the open two-arm parallel randomized controlled trial in 4 Dutch hospitals was psychological distress at post-test directly after the intervention and at 3-month follow-up. Secondary outcomes were physical and mental health-related quality of life (HRQoL), self-efficacy, chronic disease self-management, and personalized outcomes, i.e., perceived progress compared to the previous time point on functioning (e.g., mood or social functioning) and self-management (e.g., dietary or medication adherence) outcomes that were prioritized by each individual.
RESULTS: Linear mixed-effects analyses showed no significant time-by-group interaction effects for psychological distress, HRQoL, self-efficacy, and chronic condition self-management, whereas ANCOVAs showed significantly more perceived progress in the intervention group at post-test on personally prioritized areas of functioning, b = 0.46, 95%CI[0.07, 0.85], and self-management, b = 0.55, 95%CI[0.16, 0.95], with Cohen's ds of 0.46 and 0.54 (medium effects), respectively. Effects on personalized outcomes were maintained at follow-up.
CONCLUSIONS: Compared to regular care only, the eHealth intervention did not reduce psychological distress, whereas personalized outcomes did improve significantly post-intervention. Future studies could consider personalized outcomes that reflect individually relevant areas and treatment goals, matching person-tailored treatments.Trial Registration: Registered at the Netherlands Trial Register with study number NTR7555 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR7555).
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app